Clinical application of drug screening in circulating tumor cells in patients with breast cancers

Clinical application of drug screening in circulating tumor cells and exploring the impact of tumor microenvironment on the drug responses in patients with breast cancers

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN10116660

Enrollment

Registered

2024-08-29

Start date

2020-03-05

Completion date

Unknown

Last updated

2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical application of drug screening in circulating tumor cells in patients with breast cancers Cancer

Interventions

This study will investigate the clinical impact of circulating tumor cells (CTCs) in drug screening for the survival of patients with breast cancer. While the predictive value of CTCs is well establis

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Newly diagnosed primary locally advanced female breast cancer patients

Exclusion criteria

Exclusion criteria: 1. Participants undergoing primary surgery 2. Without informed consent

Design outcomes

Primary

Measure	Time frame
Correlation between anti-cancer drug tests and patient's clinical outcome measured using data collected from patient medical records as the evaluation of drug response between baseline and 3 to 6 months after treatment	—

Secondary

Measure	Time frame
The prognostic and predictive role of the count of circulating tumor cells (CTCs) measured using a fluorescence microscope to count CTCs and CTC-white blood cells (WBCs) at baseline, 3 to 6 months after treatment	—

Countries

Taiwan

Contacts

Public ContactHsu-Huan Chou

b9002009@cgmh.org.tw+886919932188

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026